FOX CHASE CHEMICAL DIVERSITY CENTER, INC

Basic Information

3805 OLD EASTON RD
DOYLESTOWN, PA, 18902-8400

Company Profile

n/a

Additional Details

Field Value
DUNS: 828761002
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Small Molecule Inhibitors of HIV1 Nef Virulence Factor for Treatment of HIV_AIDS

    Amount: $225,000.00

    DESCRIPTION: While HIV/AIDS can be managed with antiretroviral drugs that block viral replication, these agents do not clear the virus and require life-long drug administration with associated risks o ...

    STTR Phase I 2014 Department of Health and Human Services
  2. Small Molecule Antagonists of PF4 for the Treatment and Prevention of HIT

    Amount: $225,000.00

    We have discovered the first-ever inhibitors of PF4, a platelet protein central to the pathophysiology of heparin induced thrombocytopenia (HIT). Heparin is a naturally-occurring anticoagulant that pr ...

    STTR Phase I 2014 Department of Health and Human Services
  3. A Novel Therapeutic for Invasive Candidiasis

    Amount: $1,500,000.00

    DESCRIPTION (provided by applicant): Systemic fungal infections are increasingly common, especially in immune compromised patients. While new antifungal drugs have been developed, there is still a hig ...

    SBIR Phase II 2014 Department of Health and Human Services
  4. DC-SIGN Inhibitors for the Treatment of HIV Infection

    Amount: $300,000.00

    DESCRIPTION (provided by applicant): DC-SIGN (dendritic cell specific ICAM-3-grabbing non-integrin), a membrane protein of C-type lectin family, is found in high levels on monocyte-derived DCs, some m ...

    STTR Phase I 2013 Department of Health and Human Services
  5. New therapeutics for the treatment of Acinetobactor baumannii infections.

    Amount: $300,000.00

    DESCRIPTION (provided by applicant): Acinetobacter are strictly aerobic, non-fermentative Gram-negative bacilli that are of major concern in human health, in particular the species Acinetobacter bauma ...

    STTR Phase I 2013 Department of Health and Human Services
  6. Riluzole Prodrugs for Melanoma and ALS

    Amount: $1,919,724.00

    DESCRIPTION (provided by applicant): We have identified a novel Type IIb prodrug of riluzole, FC-311, which has the potential to revolutionize therapy for the treatment of the devastating condition of ...

    SBIR Phase II 2013 Department of Health and Human Services
  7. Riluzole Prodrugs for Melanoma and ALS

    Amount: $336,255.00

    DESCRIPTION (provided by applicant): Metastatic melanoma has few treatment options, and the current therapeutic standard of care is dacarbazine which is a highly cytotoxic drug with severe side effect ...

    SBIR Phase I 2011 Department of Health and Human Services
  8. Pathogen-Specific Regulation of Protein Assembly

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): One sixth of the world's population has an infectious disease, and new agents involving novel mechanisms less likely to engender resistance are needed if for no ot ...

    SBIR Phase I 2009 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government